Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-930 in advanced solid tumors
NCT05228015Phase 1Terminated
- Sponsor
- ImageneBio
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of IK930 in solid tumor (advanced stage), malignant pleural mesothelioma (MPM), epithelioid hemangioendothelioma (EHE) and 2 more (3 arms), sponsored by ImageneBio. Primary endpoints: Safety and tolerability of IK-930 at 36 months, Occurrence of Dose Limiting Toxicity at 1 year and 1 more. Started Jan 2022; status: terminated.
02
Drugs
IK930
03
Conditions
solid tumor (advanced stage)malignant pleural mesothelioma (MPM)epithelioid hemangioendothelioma (EHE)solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05228015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228015.